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PASNet: pathway-associated sparse deep
neural network for prognosis prediction from
high-throughput data
Jie Hao1, Youngsoon Kim2, Tae-Kyung Kim3,4 and Mingon Kang1,2*
Abstract
Background: Predicting prognosis in patients from large-scale genomic data is a fundamentally challenging
problem in genomic medicine. However, the prognosis still remains poor in many diseases. The poor prognosis may
be caused by high complexity of biological systems, where multiple biological components and their hierarchical
relationships are involved. Moreover, it is challenging to develop robust computational solutions with
high-dimension, low-sample size data.
Results: In this study, we propose a Pathway-Associated Sparse Deep Neural Network (PASNet) that not only predicts
patients’ prognoses but also describes complex biological processes regarding biological pathways for prognosis.
PASNet models a multilayered, hierarchical biological system of genes and pathways to predict clinical outcomes by
leveraging deep learning. The sparse solution of PASNet provides the capability of model interpretability that most
conventional fully-connected neural networks lack. We applied PASNet for long-term survival prediction in
Glioblastoma multiforme (GBM), which is a primary brain cancer that shows poor prognostic performance. The
predictive performance of PASNet was evaluated with multiple cross-validation experiments. PASNet showed a higher
Area Under the Curve (AUC) and F1-score than previous long-term survival prediction classifiers, and the significance
of PASNet’s performance was assessed by Wilcoxon signed-rank test. Furthermore, the biological pathways, found in
PASNet, were referred to as significant pathways in GBM in previous biology and medicine research.
Conclusions: PASNet can describe the different biological systems of clinical outcomes for prognostic prediction as
well as predicting prognosis more accurately than the current state-of-the-art methods. PASNet is the first
pathway-based deep neural network that represents hierarchical representations of genes and pathways and their
nonlinear effects, to the best of our knowledge. Additionally, PASNet would be promising due to its flexible model
representation and interpretability, embodying the strengths of deep learning. The open-source code of PASNet is
available at https://github.com/DataX-JieHao/PASNet.
Keywords: Sparse deep neural network, Prognosis prediction, Long-term survival prediction, Pathway-based analysis,
Glioblastoma multiforme, TCGA
Background
Predicting prognosis in patients from large-scale genomic
data is a fundamentally challenging problem in genomic
medicine [1–3]. Along with the rapid advances of high-
throughput technologies and their effectivenesses, high-
dimensional genomic data provides more accurate and
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richer biological descriptions of clinical phenotypes of
interests than ever before. Therefore, translating large-
scale genomic profiles to clinical outcomes not only
improves predicting patient prognosis but also helps in
identifying prognostic factors and biological processes.
The capabilities of high-level biological representa-
tion and interpretation of the prognosis are often more
desired in biomedical research rather thanmerely improv-
ing predictive performance. Pathway-based analysis is an
approach that a number of studies have been investigating
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to improve both predictive performance and biologi-
cal interpretability [4–6]. In pathway-based analyses, the
incorporation of biological pathway databases in a model
takes advantage of leveraging prior biological knowledge
so that potential prognostic factors of well-known biolog-
ical functionality can be identified. Pathway-based analy-
ses identify biological links between pathways and clinical
outcomes and enable the interpretation of biological pro-
cesses where their corresponding genes and proteins are
involved. Thus, pathway-based interpretation and visu-
alization provide an intuitive and comprehensive under-
standing of functionally-related molecular mechanisms.
Moreover, pathway-based approaches have shownmore
reproducible analysis results than gene expression data
analysis alone [4, 7–10]. High-level representations of
gene co-expressions are considered in most pathway-
based analyses; each of which represents a biologi-
cal pathway while preserving the original information.
Thus, pathway-based analyses remedy the limitations of
gene expression data, which are intrinsically sensitive to
stochastic fluctuations and are often caused by multi-
ple potential sources, such as inherent stochasticity of
biochemical processes, environmental differences, and
genetic mutation [11]. Pathway-based markers were pro-
posed for classifying breast cancer metastasis and ovarian
cancer survival time [5]. Cancer subtypes were discovered
with pathway-based markers via Restricted Boltzmann
Machine (RBM) [8]. A group LASSO-based approach
associated genes with pathways and characterized them
based on biological pathways [10]. Higher-order func-
tional representation of pathway-based metabolic fea-
tures provided reproducible biomarkers for breast cancer
diagnosis [9].
However, reliable and accurate prognosis still remains
poor in many diseases due to the following challenges:
high-dimension, low-sample size data and complex non-
linear effects between biological components.
Genomic data are highly dimensional relative to their
sample sizes. High-dimension, low-sample size (HDLSS)
data often make prediction models sensitive to noise
and false positive associations, which consequently make
predicting accurate prognoses difficult. LASSO-based
approaches have been mainly considered to estimate the
effects of a gene set that are associated with various types
of clinical outcomes on HDLSS data. The LASSO-based
approaches embed sparse coding schemes into linear or
logistic regression models for selecting few but greatly
informative features among the high-dimensional data.
For instance, a logistic regression with sparse regulariza-
tion was applied for the prognostic model of mortality
after acute myocardial infarction [12]. Random LASSO
was proposed to enhance the LASSO solution by apply-
ing multiple bootstrapping and was applied to predict
patients’ survival times with glioblastoma gene expression
data [13]. LASSO-based regression models as a predic-
tion model were validated with multiple imputed data in
chronic obstructive pulmonary disease patients [14].
Pathway-based analysis also helps to reduce data dimen-
sionality. The number of biological pathways is relatively
smaller than the number of genes, and a set of genes in
the same pathway can be represented by the pathway’s
effect. Thus, pathways can be used as summary variables
for the input of the predictive model instead of includ-
ing all genes, which consequently reduces the model
complexity.
Most association studies between a gene set and vari-
ous clinical outcomes have considered linear or logistic
regression models for identifying prognostic factors as
well as understanding a biological mechanism of the pro-
gression of disease. However, nonlinear effects of genes
or pathways may fail to be identified by linear-based
approaches. As a solution, kernel-based models have
been proposed to capture nonlinear effects of complex
pathways [15, 16]. Multiple kernel learning models were
introduced to aggregate complex effects from multiple
pathways [17, 18]. Kernel Principle Component Analy-
sis (KPCA) was applied to reduce the dimensionality of
the feature space by using the correlation structure of the
pathways [18].
Recently, several attempts to capture hierarchical effects
of genes and pathways have been made. Inferences of
multilayered hierarchical gene regulatory networks have
been considered to understand how pathways regulate
each other hierarchically. A bottom-up graphic Gaussian
model [19] and a recursive random forest algorithm [20]
were proposed to constructmultilayered hierarchical gene
regulatory networks. Moreover, complex biological net-
works were modeled by inferring the multiple hierarchical
models (1) between gene expression and pathways and
(2) within pathways [21]. However, complex hierarchical
relationships between pathways have not been considered
for prognostic studies yet, to the best of our knowledge,
although hierarchical effects of pathways are prevalent in
biological systems [22].
In this paper, we propose a Pathway-Associated Sparse
Deep Neural Network (PASNet) to achieve the goals:
(1) to predict prognosis in patients accurately by incor-
porating biological pathways, (2) to provide a solution
for hierarchical interpretation of nonlinear relationships
between biological pathways of disease systematically,
and (3) to handle computational problems on HDLSS
data with unbalanced classes. An innovative aspect of
our model is biological interpretability; we achieved this
with sparse coding and by constructing hidden layers
with biological pathways, which oppose the black box
nature of deep learning. Our new sparse deep learn-
ing architecture represents multiple molecular biological
layers, such as a gene layer and a pathway layer, along
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with their hierarchical relationships, which use sparse
regularization.
Results
Pathway-Associated Sparse Deep Neural Network (PAS-
Net) identifies a subset of genes and pathways involved
in a disease as prognostic biomarkers, as well as their
interactions. PASNet models a multilayered, hierarchical
biological system of genes and pathways on a disease,
while leveraging the strengths of deep learning for com-
petitive predictive performance. The sparsity of PASNet
allows one to interpret the model, which is what con-
ventional fully-connected networks lack. The architecture
of PASNet and the strategies for training a sparse neu-
ral network model with HDLSS and imbalanced data are
described in “Methods” section.
We conducted experiments to evaluate PASNet’s pre-
dictive performance for long-term survival prediction in
Glioblastoma multiforme (GBM). The capability of the
prediction was assessed by comparing our model with the
classifiers that have been used for long-term survival pre-
diction. Furthermore, we will describe how PASNet can
represent the biological system of GBM in the following
section.
Data
GBM is a primary brain cancer that shows poor prog-
nosis performance due to the above challenges. Com-
prising more than half of all brain tumors, GBM is the
most prevailing and aggressive malignant type of primary
astrocytomas [23]. Patients with GBM have a median
survival time of approximately 15 months with inten-
sive treatments [24]. Furthermore, long-term survival
patients with GBM are rare as more than 90% of patients
are deceased within three years of diagnosis. Although
treatments in neurosurgery, chemotherapy, and radio-
therapy have improved, the prognosis of GBM remains
poor [25]. Hence, the advancement in understanding
molecular mechanisms and related biological pathways of
GBM is significant to accelerating the progress for new
treatments [24].
We used the gene expression data of GBM patients,
which is available at The Cancer Genome Atlas (TCGA,
http://cancergenome.nih.gov). The dataset includes the
gene expression data of 522 samples and 12,042 genes
and provides survival time and status. We considered
patients who survived past 24 months (regardless of sur-
vival status) as long-term survivals (LTS) and patients that
deceased in less than 24 months as short-term survivals
(non-LTS). Living patients with a survival time of less than
24 months were excluded in the experiments and consid-
ered censored data. Finally, we obtained 99 LTS and 376
non-LTS samples, where around 20% of the samples were
LTS patients.
For pathway-based analysis, we utilized a biologi-
cal pathway database from the Molecular Signatures
Database (MSigDB) [26]. In MSigDB, we extracted the
biological pathways of Reactome. Then, we excluded
the pathways that include less than ten genes, because
small pathways are often redundant with larger path-
ways. As the input features, we considered the genes
that belong to at least one pathway, since pathway anno-
tations of genes are essential to construct the mask
matrix M between the gene layer and the pathway
layer. Finally, we considered 574 pathways and 4359
genes in the experiments. The gene expression data
were standardized to a mean of zero and a standard
deviation of one.
Experimental setting
We followed a typical design of conventional deep neural
networks for PASNet. A sigmoid function and cross-
entropy were considered for the activation and the cost
function, respectively. A softmax function was used in the
output layer so that the probabilities of output nodes add
up to one. For the optimal tuning of PASNet’s training, we
empirically determined the hyper-parameters by random
search before cross-validation experiments. The learning
rate (η) was set to 1e−4, and L2 regularization (λ) was set
to 3e−4. Adaptive Moment Estimation (Adam) was per-
formed as the stochastic optimizer [27]. The dropouts for
two intermediate layers were also applied with a dropping
probability of 0.8 and 0.7, respectively. PASNet was imple-
mented by PyTorch, and the source code is available at
https://github.com/DataX-JieHao/PASNet.
Comparison
We evaluated PASNet by comparing the performance
with classifiers that have been used for prognosis predic-
tion: Support Vector Machine (SVM), Random LASSO
[13], LASSO Logistic Regression (LLR) [1], and neural
network with dropout (Dropout NN).
Specifically, we used a SVM with a radial basis function
(RBF) kernel (γ = 2−16 and C = 23.9 by two-step grid
search [28]). Random LASSO was trained so that every
feature could be selected 20 times on average by boot-
strapping, and the L1 regularization parameter was deter-
mined by 10-fold cross-validation. The LASSO parameter
for LLR was also selected by 10-fold cross-validation.
The fully-connected Dropout NN was designed with the
same numbers of intermediate layers and neurons as
the proposed PASNet as well as the dropout probabili-
ties. The learning rate was 0.01 and the L2 regulariza-
tion was 0.005. Note that PASNet has less number of
weights to be trained in each epoch because of sparse
coding, compared to Dropout NN. Hence, the optimal
hyper-parameters of L2 regularization and learning rate
should be different between PASNet and Dropout NN.
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We empirically searched the optimal hyper-parameters
for PASNet and Dropout NN separately through multiple
experiments. Dropout NN was implemented by PyTorch
(https://pytorch.org/).
The experiments were carried out by stratified 5-fold
cross-validation for maintaining the same proportions
of the imbalanced samples in the classes. The cross-
validation experiments were repeated ten times for per-
formance reproducibility. Data preprocessing, such as
data normalization, was separately applied on each fold.
The testing data on each fold was scaled with the
mean and standard deviation of the training data of the
same fold.
The predictive performances of the five models were
evaluated with two metrics: Area Under the Curve (AUC)
and F1-scores. The Receiver Operating Characteristic
(ROC) curve (see Fig. 1) was traced over the thresholds
of scores to examine the trade-off between True Posi-
tive Rate (TPR = TP/(TP + FN)) and False Positive
Rate (FPR = FP/(FP + TN)), where LTS was considered
positive. An AUC was computed by the area under the
ROC curve. An F1-score, an average of Positive Predicted
Value (PPV = TP/(TP + FP)) and TPR, is calculated by
2(PPV ×TPR)/(PPV +TPR). The F1-score was computed
for the LTS class.
The average AUC and the average F1-score of the five
methods on the test datasets are shown in Table 1. PAS-
Net outperformed others as both AUC and F1-score are
relatively high. PASNet produced AUC of 0.6622±0.013
(mean±std) and F1-score of 0.3978±0.016. Following
PASNet, Dropout NN produced AUC of 0.6408±0.014,
and SVM produced AUC of 0.6337±0.015.
To statistically assess the performance of PASNet (AUC)
as compared to others, we conducted the Wilcoxon
signed-rank test: a non-parametric paired, two sided test
for the null hypothesis that states the median difference
in paired samples is zero. Specifically, the null hypothesis
is that the benchmark classifier has equal or better per-
formance than our proposed algorithm. Table 2 shows the
performance of PASNet is significantly better than others,
where the null hypotheses are rejected at the 5% signif-
icance level (p-value <0.05). Hence, the outperformance
of PASNet was statistically significant compared to the
benchmark classifiers.
SVM and Dropout NN showed a higher AUC than
LASSO logistic regression and Random LASSO, prob-
ably because of their capability of capturing nonlinear
effects of genes. Compared to Dropout NN, PASNet is a
relatively thin network, where the connections between
layers are very sparse. However, PASNet interestingly pro-
duced higher performance than Dropout NN. It shows
that PASNet builds a robust network model, which
is simplified to represent the biological processes for
prognosis prediction by incorporating biological prior
knowledge.
Discussion
Although PASNet yielded competitive predictive perfor-
mance in the experiments, a more promising contribution
of PASNet is in the model’s interpretability. In this section,
we demonstrate a plausible biological mechanism inferred
by PASNet for long-term survival prediction in GBM. The
graphical representations of the PASNet model are illus-
trated in Figs. 2, 3 and 4 in the top-down order. The
Fig. 1 ROC Curves. PASNet produces the highest AUC of 0.6622 while the AUC of Dropout NN, SVM, random LASSO, and LLR is 0.6408, 0.6337,
0.6209, and 0.5899, respectively
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Table 1 Comparison of AUC and F1-score in over ten stratified
5-fold cross-validations
Model AUC F1-Score
Logistic LASSO 0.5899±0.020 0.3347±0.025
Random LASSO 0.6209±0.020 0.3370±0.020
SVM 0.6337±0.015 0.3446±0.015
Dropout NN 0.6408±0.014 0.2957±0.025
PASNet 0.6622±0.013 0.3978±0.016
heatmaps were generated by sorting the weights and node
values of LTS, and positive and negative weight values are
colored in red and blue, respectively.
First, Fig. 2 manifests the posterior probability of the
samples in the clinical outcomes. The dark block on the
top shows the output node values (−log2(node value)) of
the LTS samples, while the remaining ones are non-LTS
samples. The weight values of the connections from hid-
den nodes to the output nodes are depicted in Fig. 3a,
where dropped connections are colored in white. The
figure reveals distinct patterns of weights (opposite signs)
to the two output neurons. Note that there are hidden
nodes disconnected to the neurons in the output layer
(colored in white) by sparse coding, which shows that the
hidden nodes are insignificant.
The hidden node values of the samples are shown in
Fig. 3b. The values of the hidden nodes indicate the
intensity of the group effects on the pathways, which are
connected to the hidden nodes. For instance, the first
16 hidden nodes in Fig. 3b show distinguishable inten-
sities on LTS and non-LTS patients. The LTS patients
present significant intensities of the group effects of the 16
pathways while non-LTS patients show significant lower
values.
The weights between the pathway nodes and the hidden
nodes are exhibited in Fig. 3c, and the top-10 ranked path-
ways among them are zoomed in Fig. 4a. It appears that a
small number of pathwaysmainly contribute to the hidden
nodes simultaneously, which implies that the cohort of the
pathways may be candidates of prognostic biomarkers in
long-term survival of GBM. The top-10 ranked pathways
include signaling by GPCR, GPCR downstream signal-
ing, innate immune system, adaptive immune system,
Table 2 The Wilcoxon signed-rank tests for comparing PASNet
with the Benchmark Classifiers
W Statistic P-value
PASNet vs. Dropout NN 146.5 2.13e-06
PASNet vs. RBF-SVM 137.0 1.35e-06
PASNet vs. Random LASSO 45.0 1.06e-08
PASNet vs. Logistic LASSO 43.0 9.52e-09
metabolism of carbohydrates, transmembrane transport
of small molecules, developmental biology, metabolism of
proteins, class A/1 (rhodopsin-like receptors), and axon
guidance. Most of the pathways are referred to as sig-
nificant pathways in GBM in biological literature. The
pathways and the references are listed in Table 3. Since
the top-10 ranked pathways are all large (gene numbers
> 200), we further explored small pathways as well. Class
B/2 (Secretin family receptors) pathway which includes
88 genes is ranked 14th. One of the subgroups in Class
B/2 family is categorized as brain-specific angiogenesis
inhibitors that are growth suppressors of glioblastoma
cells [29]. Hence, Class B/2 pathway may play an impor-
tant role in inhibition of GBM.
The genes of the pathways are illustrated by the weight
values in Fig. 4b. Since the connections between the
gene layer and the pathway layer are given by path-
way databases, e.g., Reactome, they are very sparse. It
also shows that multiple pathways share genes in com-
mon. The genes, which are most frequently shown in
the ten pathways, include CDC42, PRKCQ, RAC1, AKT1,
AKT2, AKT3, C3, CREB1, GRB2, HRAS, KRAS, NRAS,
PRKACA, PRKACB, PRKACG, RAF1, and YWHAB,
where CDC42, PRKCQ, and RAC1 are shown in six path-
ways and others are in five pathways. Among them, several
genes have been reported as biomarkers in GBM. For
instance, AKT1, AKT2, and AKT3, belonging to the five
pathways of signaling by GPCR, GPCR downstream sig-
naling, innate immune system, adaptive immune system,
and developmental biology, are three isoforms of AKT in
PI3K/AKT pathway, which is an important drug target in
many cancers including GBM [30]. In particular, AKT2 is
a well-known proto-oncogene that promotes the growth
of tumors and reduces the survival of patients in GBM
[31, 32].
Finally, we demonstrate a hierarchical representation of
genes and pathways in PASNet. In Fig. 5a, PASNet is par-
tially visualized, where positive and negative weights are
colored in red and blue respectively. The pathways are
represented by the corresponding genes in the pathway
layer, and then the nonlinear effects of the pathways are
described in the hidden layer. The hierarchical representa-
tions can be captured in the output layer, which produces
a posterior probability for prognosis prediction. Although
we considered a single hidden layer to simplify the model
with HDLSS data in this study, multiple hidden layers
may be able to capture the biological processes and their
effects more accurately if a sufficient number of samples
are available. Figure 5b–c illustrate distinctive representa-
tions of LTS and non-LTS samples in PASNet. The color
of nodes in the figures shows the values computed with
LTS/non-LTS samples in average. Note that node val-
ues between the pathway layer and the output layer are
between zero and one. The node with a high value may be
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Fig. 2 Graphical representation of the output node values over the samples by PASNet. LTS samples obtain higher node values in LTS node than
non-LTS samples. Similarly, non-LTS samples obtain higher node values in non-LTS node than LTS samples
a potential prognostic biomarker in the group. Figure 5b
shows that pathways including aquaporin-mediated trans-
port, signaling by BMP, and cytokine signaling in immune
system are activated with LTS samples. The second node
in the hidden layer is triggered by the active pathways,
and the hidden node activates the LTS node in the out-
put layer. On the other hand, Fig. 5c shows that additional
pathways of signaling by GPCR and innate immune sys-
tem are also activated for non-LTS samples. The other
two hidden nodes take the active pathways into account,
and they activate the non-LTS node in the output layer.
Hence, the two pathways of signaling by GPCR and innate
immune system may be potential prognostic biomark-
ers for predicting LTS/non-LTS. Pathway of signaling by
GPCR has been investigated as a potential therapeutic tar-
get to inhibit the progression of glioblastomas. [33]. Acti-
vating the innate immune system, i.e. immunotherapy,




Fig. 3 Graphical representation among the output layer, hidden layer, and pathway layer in PASNet. (a) The weights between the hidden layer and
the output layer. Hidden nodes are sorted in a descending order. (b) The node values in the hidden layer. The horizontal dotted lines indicates
LTS/non-LTS samples. The vertical dotted lines indicates LTS/non-LTS samples are significantly distinguished by top 16 pathways. (c) The absolute
weights between the pathway layer and the hidden layer
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Fig. 4 Graphical representation of the 10 top-ranked pathways by PASNet (a) The absolute weights between the 10 top-ranked pathway nodes and
the hidden layer. It is a zoom-in view of Fig. 3c. (b) Weights between the gene layer and the 10 top-ranked pathway nodes. The connections are
determined by Reactome database
Vascular endothelial growth factor (VEGF), a modula-
tor of the innate immune system, is reported crucial
for the tumor progression [35]. Moreover, aquaporin-
mediated transport, signaling by BMP, and cytokine sig-
naling in immune system may play an important role in
GBM, since they are shown in common as active in both
LTS and non-LTS. Note that the activation/inactivation
of a node in PASNet does not directly represent bio-
logical activation in the system, whereas it indicates
different states of the biological components in the
groups.
Conclusions
In this paper, we proposed pathway-associated sparse
deep neural network for prognosis predictions (long-
term survivals in GBM in this study). PASNet builds a
network model by leveraging prior biological knowledge
of pathway databases and by taking hierarchical nonlin-
ear relationships of biological processes into account. To
improve the model interpretability, PASNet introduces
sparse coding. Moreover, we developed a training strategy
to avoid the overfitting problem with HDLSS data and the
imbalanced problem.
Table 3 Top-10 ranked pathways for survival prediction in GBM by PASNet
Pathway name Pathway size Reference Top-5 ranked genesa
Signaling by GPCR 920 [33] SHH, PTGFR, GNG5, CHRM5, LHB
GPCR downstream signaling 805 [50] PTGFR, OR7C2, GNG5, OR10H3, MLNR
Innate immune system 933 [35] CD79B, INPPL1, SRC, NUP85, DNM2
Adaptive immune system 539 [51] CD79B, ASB6, PTEN, NCF4, FBXO2
Metabolism of carbohydrates 247 - HS3ST3B1, NUP85, PFKFB3, LUM, SLC2A4
Transmembrane transport of small molecules 413 [52] SLC9A7, ABCA7, GNG5, AQP8, HK3
Developmental biology 396 - NRP2, FES, WNT10B, MYOD1, SLC2A4
Metabolism of proteins 518 - EIF3G, CCT2, TIMM22, RPL3L, GMPPA
Class A/1 (rhodopsin-like receptors) 305 [53] PTGFR, OPRD1, CHRM5, NPFF, NTSR2
Axon guidance 251 [54] NRP2, NRTN, AGRN, FES, RPS6KA4
a
The genes were ranked by absolute weights in the pathways
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Fig. 5 Hierarchical representation of pathways in PASNet. (a) PASNet is partially visualized showing the five pathways. Distinct neural network
activations between LTS (b) and non-LTS (c) are shown via PASNet. The nodes of the neural network of (b) and (c) correspond to (a). For instance,
the nodes in the pathway layer of (b) and (c) represent signaling by GPCR, innate immune system, aquaporin-mediated transport, signaling by BMP,
and Cytokine signaling in immune system. The pathways of signaling by GPCR and innate immune system are inactive with LTS patients, whereas
the both pathways are active with non-LTS patients
To investigate the performance of PASNet, we used
gene expression data of GBM patients in TCGA. PASNet
was assessed by comparing the predictive performance
with support vector machine, random LASSO, LASSO
logistic Regression, and neural network with dropout that
have been widely used for prognosis prediction. PAS-
Net outperformed them with respect to both AUC and
F1-score in the multiple stratified 5-fold cross-validation
experiments. Furthermore, we discussed how PASNet can
describe the biological system of GBM.
PASNet is the first deep neural network-based model
that represents hierarchical representations of genes and
pathways and their nonlinear effects, to the best of our
knowledge. Additionally, PASNet would be promising due
to its flexible model representation and interpretability,
embodying the strengths of deep learning.
Methods
The architecture of PASNet
PASNet incorporates biological pathways and the con-
cept of sparse modeling based on Deep Neural Network
(DNN). The neural network architecture of PASNet con-
sists of a gene layer (an input layer), a pathway layer
that represents the biological pathways linked with input
genes, a hidden layer that represents hierarchical relation-
ships among biological pathways, and an output layer that
corresponds with clinical outcomes, e.g. a binary class that
has long-term survival and short-term survival, stages of
cancer (see Fig. 6).
In PASNet, sparse coding is considered on the
connections between layers for model interpretability.
Sparse coding provides a solution to capture signif-
icant components of a biological mechanism in the
Fig. 6 Architecture of PASNet. The structure of PASNet is constructed by a gene layer (an input layer), a pathway layer that represents the biological
pathways linked with input genes, a hidden layer that represents hierarchical relationships among biological pathways, and an output layer that
corresponds with clinical outcomes, e.g. a binary class that has long-term survival and short-term survival, stages of cancer
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model, since biological processes may involve only a few
biological components. On the other hand, conventional
fully-connected networks lack to represent biological
mechanisms.
Gene layer
The gene layer (as an input layer) corresponds to gene
expression data. A patient sample of m gene expres-
sions is formed as a column vector, which is denoted by
x = {x1, x2, ..., xm}. Each input node represents one gene
feature.
Pathway layer
The pathway layer represents biological pathways, where
each node indicates an individual pathway. The connec-
tions between the gene layer and the pathway layer are
established by well-known pathway databases (e.g., Reac-
tome and KEGG). Pathway databases contain associations
between pathways and genes; each of which provides a set
of gene components. Therefore, the pathway layer makes
it possible to interpret the model as a pathway-based
analysis.
To begin with initializing the connections between
the gene layer and the pathway layer, we consider a
binary biadjacency matrix (A) from biological pathway
databases. The biadjacency matrix can be defined as A ∈
B
n×m, where n is number of pathways and m is number
of genes. Then, an element of A, i.e., aij, is set to one if
gene j belongs to pathway i; otherwise, zero. Sparse cod-
ing is applied based on the matrix A to represent the
relationships between genes and pathways in the model.
Hidden layer
Biological components may cooperate with others instead
of functioning alone. A biological system involves multi-
ple pathways which have interactions together, whereas a
node in the pathway layer indicates a biological pathway.
The associative interactions between pathways can be rep-
resented in the hidden layer. In PASNet, the hidden layer
represents biological nonlinear associations between the
pathways to outputs.
Sparse coding between the pathway and the hidden lay-
ers enables one to interpret these relationships. Although
we consider only a single hidden layer in this study
for simplicity’s sake, multiple hidden layers can be used
for deeper hierarchical representations of pathways. For
example, if there are two hidden layers, the second hid-
den layer will represent deeper hierarchical associations of
the nodes of the first hidden layer, which are association
effects of pathways.
Output layer
The output layer shows clinical outcomes for which nodes
compute the posterior probabilities. In this layer, sparse
coding allows to distinguish hierarchical groups of path-
ways (which are detected from hidden layers) to predict
clinical outcomes. In PASNet, more than two clinical
outcomes can be easily represented with multiple nodes
in the output layer.
Consequently, PASNet can dissect distinguishable bio-
logical processes of hierarchical nonlinear relationships
and associations of genes and pathways to predict clini-
cal outcomes. Furthermore, this generative model-based
approach would be often useful to predict prognosis accu-
rately with complex data of HDLSS. When data is highly
complex and only small sample sizes are available, model
optimization may be easily biased to the training data
rather than providing a general solution. On the other
hand, the integration of the biological structures and
prior knowledge to the model would produce a robust
solution.
Overall description of PASNet training
The main challenge in training PASNet is to reduce both
risk of overfitting and computational complexity of train-
ing on HDLSS data. The related works that have han-
dled the HDLSS data problem are discussed in “Related
works in deep learning” section. To unravel the problems,
PASNet optimizes a small sub-network, which involves
feasible nodes and parameters to train instead of the whole
network and then makes the sub-network sparse. Figure 7
illustrates the overall training flow of PASNet.
a b c
Fig. 7 Training of PASNet. (a) Weights and biases are randomly initialized. Connections between the gene layer and the pathway layer are
determined by biological pathway databases, and the remaining layers are considered as fully-connected in this step. (b) A sub-network is randomly
selected using a dropout technique and trained. (c) Sparse coding optimizes the sparsity of connections in the sub-network
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First, we initialize the connections between the gene
layer and the pathway layer with prior biological knowl-
edge of pathways (see Fig. 7a). Active/inactive connections
are determined by the biadjacency matrix, A. The weights
of active connections and biases are randomly initialized
from standard normal distribution, while the weights of
inactive connections are set to zero. The sparsity of the
connections between the gene layer and the pathway layer
is invariant over the entire training. The remaining layers
are fully interconnected as the initial.
In the training phase, we repeat training sub-networks
and applying sparse coding on the sub-networks until
convergence (Fig. 7b–c). A sub-network is selected by a
dropout technique, where neurons are randomly dropped
in the intermediate layers. In Fig. 7b, a small sub-
network is shown with bold solid circles and lines. Then,
the small sub-network is trained by feed-forward and
backpropagation. Note that only weights and biases of
the sub-network are trained. Upon the completion of the
sub-network’s training, sparse coding is applied to the
sub-network by trimming the connections that do not
contribute or worsen to minimize the loss. In Fig. 7c,
the dropped connections and nodes are marked as bold,
dashed lines. The details of the training are elucidated in
the following sections.
Sparse coding
Once a small sub-network is completed to train with the
HDLSS data, the sub-network is imposed to be sparse
for the model interpretation. The sparsity of the sub-









where  denotes element-wise multiplication, and a(·) is
an activation function. h() denotes an output vector on
the -th layer, and W() and b() are a weight matrix and
a bias vector, respectively. An element value ofM is either
one or zero, which determines whether the associated
weights are dropped in the current epoch.
The mask matrix M is generated with respect to a
sparsity level (S) that indicates the proportion of weights
to be dropped in a single layer. S is a value between 0
to 100, where zero creates a fully-connected layer while
100 causes no connection. The optimal S∗ is approx-
imated on each layer individually in the sub-network,
while most related methods consider a single hyper-
parameter for the sparsity of all layers [36, 37]. The
individual setting of the sparsity on each layer shows dif-
ferent levels of biological associations on the genes and
pathways.
We obtain the optimal sparsity level S∗ that minimizes
the cost score. For efficient computation, the cost scores
are computed with a small number of finite sparsity levels.
Then, the optimal sparsity level is estimated by apply-
ing a cubic-spline interpolation to the cost scores with
the assumption that the cost function, with respect to the
sparsity level, is continuous.
In particular, an element of M is set to one if the
absolute value of the corresponding weight is greater
than threshold Q; otherwise, the element is zero, where
Q is an S-th percentile of absolute values of W. Note
that the mask between the gene layer and the pathway
layer, i.e. M(0), is determined by the biadjacency matrix





(|W()| ≥ Q()) , if  = 0
A, if  = 0 (2)
where Q() is the S-th percentile of |W()| if  = 0.
Cost-sensitive learning for imbalanced data
We refine the cost function and the backpropagation for
cost-sensitive learning, since imbalanced data causes bias
of the predictions towards themajority class.We adapt the
Mean False Error (MFE) method [38], which penalizes the
errors of the majority class.
Let K be the number of clinical outcomes. The nor-













where Ck denotes mean error on the class k, and nk is the
number of samples in the class k. yi is a vectorized ground
truth class label of the i-th sample, and ỹi is its vectorized
prediction. c(·) denotes a cost function (e.g., cross-entropy
loss), and L is the total cost. ‖W‖2 denotes a L2-norm of
W, and λ > 0 is a regularization hyperparameter.
In the backpropagation phrase, the gradient is also com-
puted separately for each class. Hence, the weights and
biases on the -th layer are updated by:












where η is a learning rate. The algorithm of PASNet is
briefly described in Algorithm 1.
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Algorithm 1 Training of PASNet
1: Initialize weightsW() and biases b()
2: W(0) ← W(0)  M(0)
3: repeat
4: Select a small sub-network via dropout
5: Train the sub-network by Eqs. (5) and (6)
6: Sparse coding with the optimalM() by Eq. (2)
7: W() ← W()  M()
8: until convergence
Related works in deep learning
In recent years, deep learning has been spotlighted as
the most active research field in various machine learn-
ing communities, such as image analysis, speech recog-
nition, and natural language processing as its promising
potential is being actively discussed in bioinformatics and
biomedicine [39]. Most deep learning-based approaches
have been developed for classification and association
studies in bioinformatics. For instance, D-GEX infers the
expression of target genes from landmark genes, cap-
turing the nonlinear relationships by combining gene
expression, DNA methylation, and miRNA expression
data [40]. A convolutional neural network (CNN) was
adapted to predict DNA-protein binding sites with Chro-
matin Immunoprecipitation sequencing (ChIP-seq) data
[41]. Additionally, CNN-based DeepBind was proposed
to predict whether a specific DNA/RNA binding protein
will bind to a specific DNA sequence [42]. The function-
ality of non-coding variants was predicted by DeepSEA by
employing a CNN model [43].
Although only a small subset of deep learning research
has been reported in bioinformatics due to the diffi-
culty of structure definition and interpretation, the future
of deep learning in biology and medicine is promis-
ing [44]. First, since a neural network is inspired by
the neurons in the human brain, a neuron network
architecture is applicable to modeling a mechanism for
a complex biological system. Specifically, deep learn-
ing approaches take advantage of flexible representation
of hierarchical structures from inputs to outputs. The
representation of nonlinear effects of neurons in mul-
tiple layers in neural networks may be able to model
hierarchical biological signals. DCell constructs a multi-
layer neural network based on extensive prior biological
knowledge to simulate the growth of a eukaryotic cell
[45]. However, DCell’s network architecture is entirely
based on well-known prior biological knowledge, so the
model was applied to relatively simple biological sys-
tem of yeast. Moreover, deep learning captures nonlinear
effects of variables with high-level feature representa-
tion, which allows deep learning to outperform other
state-of-the-art methods.
However, training deep neural networks with HDLSS
data poses a computational problem. A large number of
parameters are involved in deep neural networks, and
it often makes the training infeasible or causes a model
overfit on HDLSS data. Particularly, backpropagation gra-
dients in neural networks are of high variance on HDLSS
data, which consequently causes the model overfit [46].
In order to tackle the HDLSS problem, the leave-one-
out approach was used to avoid the overfitting problem
in backpropagation [47]. Regarding backpropagation, the
risk of overfitting was examined with validation data by
the leave-one-out approach and terminates the training
early when overfitting occurs. For an alternative solu-
tion, an attempt to reduce the dimensionality of the input
space to a feasible size has been made [48]. Dimen-
sion reduction techniques, such as subsampled random-
ized Hadamard transform (SRHT) and Count Sketch-base
construction, were utilized to reduce the dimensional
size of the input data. Then, the projected data into
the lower space were introduced to a neural network
for training.
For HDLSS data, feature selection is one of the con-
ventional approaches. Deep Feature Selection (DFS) was
developed to select a discriminative feature subset in a
deep learning model [49]. Although DFS is not the opti-
mal solution to low-sample size data, DFS shows that deep
learning can detect informative and discriminative fea-
tures of nonlinearity effects through multiple layers with
high-dimensional data. Then, Deep Neural Pursuit (DNP)
improved the solution of the feature selection in deep
learning, taking the HDLSS data problem into account
[46]. DNP iteratively augments features in the input layer
by performing multiple dropouts. The multiple dropouts
grant the ability to train a small-sized sub-network at
a time and to compute gradients with low variance for
alleviating the overfitting problem.
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